Biomind finishes dosing in trial of inhalation therapy for treatment-resistant depression

Sep. 21, 2022 1:43 PM ETBiomind Labs Inc. (BMNDF)By: Ravikash, SA News Editor

Medical Science Laboratory with Diverse Multi-Ethnic Team of Microbiology Scientists Have Meeting on Developing Drugs, Medicine, Doing Biotechnology Research. Working on Computers, Analyzing Samples


  • Biomind Labs (OTCQB:BMNDF) said it completed dosing of 30 healthy people in a phase 2 trial of its drug BMND01 for treatment-resistant depression.
  • "The results of this first part of the world’s first clinical trial to test an inhaled formulation of DMT are expected to be ready in October 2022," said Biomind CEO Alejandro Antalich in a Sept. 21 press release.
  • The trial will evaluate the safety and and tolerability of BMND01, a N-dimethyltryptamine (DMT)-based inhaled formulation.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.